Trial Profile
Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Feb 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors Kedrion
- 29 Jan 2021 Status changed from active, no longer recruiting to completed.
- 06 Oct 2015 New trial record